18 reports

  • Hypothyroidism Trial Snapshots- 2013
  • Hypothyroidism Trial Snapshots- 2013
  • Endocrine Disease
  • World
  • Company Operations
  • Product Initiative
  • GlaxoSmithKline plc
  • APR 26, 2017: SHIRE GRANTED EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR (PARATHYROID HORMONE) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HYPOPARATHYROIDISM
  • MAY 19, 2017: SHIRE TO HIGHLIGHT NEW RESEARCH INTO CHRONIC HYPOPARATHYROIDISM AT THE EUROPEAN CONGRESS OF ENDOCRINOLOGY

Hypoparathyroidism is a rare endocrine disease resulting from an inappropriately low circulating PTH concentration.

  • Endocrine Disease
  • Therapy
  • Europe
  • United States
  • NPS Pharmaceuticals, Inc.
  • APR 26, 2017: SHIRE GRANTED EU CONDITIONAL MARKETING AUTHORISATION FOR NATPAR (PARATHYROID HORMONE) FOR THE TREATMENT OF PATIENTS WITH CHRONIC HYPOPARATHYROIDISM

Hypoparathyroidism is a rare endocrine disease resulting from an inappropriately low circulating PTH concentration.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • NPS Pharmaceuticals, Inc.

This agreement enables PeptiDream and Ipsen to discover, develop and commercialize therapeutic peptides to treat serious Endocrine diseases.

  • Blood Disease
  • Endocrine Disease
  • United States
  • Demand
  • Ipsen S.A.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

The report includes coverage of disease clinical trials by region and top countries, trial phase, trial status, end points status and sponsor type.

  • Endocrine Disease
  • Pathology
  • World
  • Product Initiative
  • Uni-Pharma SA
  • Hyperthyroidism Trial Snapshots- 2012
  • Drug Discovery And Development
  • Endocrine Disease
  • World
  • Company Operations
  • Product Initiative

There are currently no approved therapies for PCOS, which is the most common endocrine disease in women.

  • Endocrine Disease
  • Therapy
  • United States
  • World
  • Product Initiative
  • Mar 09, 2016: XOMA Reports Fourth Quarter and Full-Year 2015 Financial Results

" With our strategic focus on advancing our endocrine programs, we continue to seek ways to support and fund these efforts through discovery and licensing of our non-endocrine assets.

  • Endocrine Disease
  • Pharmaceutical
  • United States
  • Company
  • XOMA Corporation
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Cardiometabolic Disease Global Clinical Trials Review, H##, 2017 HEA LTH CA REHEA LTH CA RE REFERENCE CODE: GDHC##CTIDB PUBLICATION DATE: MAY 2017 LIST OF TABLES LIST OF FIGURES CARDIOMETABOLIC DISEASE GLOBAL CLINICAL TRIALS REVIEW, H##, 2017 OUTLINES CLINICAL TRIALS IN CARDIOMETAB

  • Endocrine Disease
  • Pathology
  • World
  • Product Initiative
  • EFFRX PHARMACEUTICALS SA
  • POLYCYSTIC OVARIAN SYNDROME - PIPELINE BY BAYER AG, H2 2017
  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative

a science-driven biopharmaceutical company that is committed to developing innovative therapeutics in the areas of osteoporosis, oncology and endocrine diseases, announced that additional positive results from the Phase ## ACTIVE (Abaloparatide Comparator Trial In Vertebral Endpo

  • Endocrine Disease
  • Hormone
  • Musculoskeletal Disorder
  • Therapy
  • World
  • XOMA Corporation - Company Statement

Our business efforts are focused on advancing the assets in our portfolio of compounds that could treat a variety of endocrine diseases.

  • Endocrine Disease
  • United States
  • World
  • Product Initiative
  • XOMA Corporation

" This program represents a significant extension of Crinetics' efforts to develop drugs that target endocrine diseases and endocrine related cancers.

  • Endocrine Disease
  • Pharmaceutical
  • Therapy
  • World
  • Crinetics Pharmaceuticals, Inc.
  • 4.1 DISEASE BACKGROUND

ENDOCRINE PRACTICE; ##(##): ##-##.

  • Endocrine Disease
  • Forecast
  • Amgen Inc.
  • Keryx Biopharmaceuticals, Inc.
  • OPKO Health, Inc.
  • 2.1 DISEASE BACKGROUND

Endocrine Connections; ##(##): ##-##.

  • Endocrine Disease
  • Japan
  • United Kingdom
  • United States
  • Forecast

FRAX is a registered trademark of The Centre for Metabolic Bone Diseases at the University of Sheffield.

  • Endocrine Disease
  • Hormone
  • Musculoskeletal Disorder
  • Therapy
  • World

ENDOCRINE HORMONES: THE PRODUCTS SECRETED BY THE ENDOCRINE GLANDS.

  • Endocrine Disease
  • Eli Lilly & Co.
  • Novo Nordisk Group
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Jiangsu Hengrui' s research and development activities focus on developing novel medicines in areas of cardiovascular, antineoplastics, endocrine system and the immune system.

  • Cardiovascular Disease
  • Chronic Disease
  • Endocrine Disease
  • United States
  • Product Initiative